Checkmate Pharmaceuticals is a clinical stage company pursuing a novel approach to specifically activating the innate and adaptive arms of the immune system to recognize and ultimately destroy tumor cells. The company is leveraging its extensive expertise and experience in the field of CpG oligonucleotides (ODN) to evaluate the ability of CMP-001 (a CpG-A ODN) to stimulate an anti-tumor T cell response in combination with checkpoint inhibition to overcome a tumor’s ability to suppress the immune response. CMP-001 is the only CpG-A in clinical development. A multicenter, open-label, Phase 1b clinical study is currently being conducted with CMP-001 in combination with pembrolizumab in patients with advanced cutaneous melanoma.
